Asked by: Jim Shannon (Democratic Unionist Party - Strangford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking help improve addiction and mental health treatment.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
We know that people with co-occurring substance use and mental health needs do not receive the integrated, person-centred care they require and deserve. The Department and NHS England have recently published the Co-occurring Mental Health and Substance Use Delivery framework, which is available at the following link:
This framework commits the Department and NHS England to delivering several national actions to improve delivery of integrated, person-centred care across drug and alcohol treatment and mental health services. The framework also includes recommended actions on how the health system can also work together to improve outcomes for those with co-occurring needs.
We also know that gambling can have a wide-ranging negative effect on health and inequalities and is associated with poor mental health and in severe cases suicide, as well as the knock-on impacts from gambling related debt. In April 2025, the statutory gambling levy came into effect to fund the research, prevention, and treatment of gambling-related harm across Great Britain. In its first year, the levy has raised nearly £120 million, with 50% allocated to gambling harms treatment activity across Great Britain.
Lastly, rates of smoking continue to fall in the general population, although inequality remains, with higher rates of smoking in other groups such as people with a mental health condition or people in routine and manual work. Stop Smoking Services are effective in reaching high-prevalence groups. By targeting support in populations with greater need, we want to secure a smoke-free generation together, where no one is left behind.
Asked by: Manuela Perteghella (Liberal Democrat - Stratford-on-Avon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help tackle the harm caused by sodium valproate to people in (a) England, (b) Warwickshire, and (c) Stratford-on-Avon.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Everyone who has been harmed from sodium valproate has our deepest sympathies.
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the NHS in Newcastle and Manchester. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, better coordination of care, and reduced reliance on emergency care. Findings from the pilot will inform future decisions on the commissioning of services, subject to funding.
The Government is also carefully considering the Patient Safety Commissioner’s recommendations made in the Hughes Report, which includes proposed approaches to redress for those harmed by sodium valproate. I recently met the Patient Safety Commissioner to provide an update on the ongoing health initiatives led by the Department regarding sodium valproate and pelvic mesh, and agreed to providing an update on her report recommendations in due course.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether NHS England plans to commission specialist multidisciplinary services for people affected by sodium valproate exposure, including care coordination, to help reduce emergency admissions and diagnostic times.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.
Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has been made of the adequacy of the diagnostic time taken and levels of misdiagnosis among individuals harmed by sodium valproate, and its impact on long-term outcomes.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.
Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment has been made of whether NHS care pathways are adequate for individuals harmed by sodium valproate that require lifelong, multidisciplinary care.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.
Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Asked by: Bob Blackman (Conservative - Harrow East)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what guidance exists for Integrated Care Boards on supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Independent Medicines and Medical Devices Safety Review, First Do No Harm, identified significant shortcomings in National Health Service care pathways for people harmed by sodium valproate, including fragmented services, limited diagnostic expertise, delays in diagnosis, and inequitable access to multidisciplinary care. NHS England has acknowledged variation in the availability and adequacy of care pathways, the impact of delayed diagnosis and misdiagnosis on long-term outcomes, and the need for improved care coordination for those requiring lifelong support.
In response, NHS England has commissioned a Fetal Exposure to Medicines Services Pilot, being delivered by the Newcastle upon Tyne Hospitals NHS Foundation Trust and the Manchester University NHS Foundation Trust. The pilot provides multidisciplinary diagnostic assessment and is informing the development of improved care pathways, including consideration of specialist multidisciplinary services to support earlier diagnosis, better coordination of care, and reduced reliance on emergency care. Initial learning was shared with NHS England in September 2025, with final recommendations expected this summer to inform decisions on any national commissioning, subject to funding.
Finally, whilst integrated care boards (ICBs) are the responsible commissioners of the majority of health services, including services related to medically induced disabilities, no specific guidance has been issued to ICBs in relation to supporting individuals with complex, medicine-induced disabilities arising from sodium valproate.
Asked by: James McMurdock (Independent - South Basildon and East Thurrock)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress he has made on implementing the recommendations of the First Do No Harm report; and if he will publish an updated timetable for delivery of those recommendations.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Seven of the nine recommendations made in the First Do No Harm report have been previously accepted in full, in part, or in principle. Four of these have been successfully implemented, including appointing Professor Henrietta Hughes as the first ever Patient Safety Commissioner in England in respect of medicines and medical devices, and establishing nine specialist mesh centres, which are in operation across England.
Whilst the Government has no plans to publish a timetable, progress is ongoing in respect of the remaining recommendations. For example, the Medicines and Healthcare products Regulatory Agency has undergone an ambitious organisation-wide transformation to ensure it becomes a progressive and responsive patient-focussed regulator of medical products, for recommendation six, the Medical Devices and Outcomes Registry is now live and healthcare providers are required to contribute data, for recommendation seven, and regarding mandatory reporting of payments for the pharmaceutical and medical device industries, the Government intends to publish its response to a public consultation on this topic later this month, for recommendation eight.
Work is also ongoing across the Government to consider the recommendations in the Hughes Report, which looked into, and provided advice on, redress for those affected by sodium valproate and pelvic mesh.
Asked by: Ben Lake (Plaid Cymru - Ceredigion Preseli)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the Independent Medicines and Medical Devices Safety Review report, published on 8 July 2020, if he will make an assessment of the potential merits of launching a public inquiry into the potential harms of anti-seizure medication.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Everyone who has been harmed following use of anti-seizure medication has our deepest sympathies. We fully understand the importance of patient safety, which is a top priority for this government. It is vital we do all we can to stop harm from happening in the first place.
The Medicines and Healthcare products Regulatory Agency rigorously monitors and reviews all emerging data and risks in relation to anti-seizure medication and communicates information on risks to patients. Following Baroness Cumberlege’s 2020 Independent Medicines and Medical Devices Safety (IMMDS) Review, which examined the anti-seizure medication Sodium Valproate in detail, several actions have been taken to ensure that valproate is only prescribed when clinically appropriate. These include ensuring valproate is not started in new patients younger than 55 years old unless two specialists independently consider and document that there is no other effective or tolerated treatment, or there are compelling reasons that the reproductive risks do not apply.
One of the conclusions of the IMMDS Review was that a public inquiry would not best serve the interests of those affected by each of the interventions covered by the review. We have no plans to launch a public inquiry into the potential harms of anti-seizure medication.
Asked by: Lord Scriven (Liberal Democrat - Life peer)
Question to the Ministry of Justice:
To ask His Majesty's Government what assessment they have made of the case of R v Mohammad Siddiqui [2025], in particular the remarks of HHJ Lucas KC that “safeguards and protections must now be put in place and put in place as a matter of urgency, to ensure that babies and young children are protected” from ritual circumcision.
Answered by Lord Ponsonby of Shulbrede
The Ministry of Justice has no responsibility for non-therapeutic male circumcision or its regulation. The Government does, however, understand and sympathise with the children and their families who experience harm or trauma as a result of the behaviour of unregulated and irresponsible practitioners. It is important that those who engage in these activities, and do not comply with the required regulations, are brought to justice.
Male circumcision performed for any other reason than a physical clinical need is termed as “non-therapeutic male circumcision”. The Government is aware that parents for religious reasons, or to incorporate a child into a community, may request such a procedure. The Government would encourage all parents to ensure that in seeking such a procedure, that they discuss the matter first with their GP or healthcare practitioner.
Where a registered healthcare professional wishes to carry out non-therapeutic male circumcision, they must be registered with the Care Quality Commission to carry out the regulated activity of surgical procedures. Even where a healthcare professional is acting in a religious or spiritual role, they cannot ‘opt out’ of their core duties and responsibilities.
Asked by: Caroline Voaden (Liberal Democrat - South Devon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the report entitled First Do No Harm: the report of Independent Medicines and Medical Devices Safety Review, published in July 2020, what progress he has made on setting up an independent Redress Agency.
Answered by Andrew Gwynne
The previous Government did not previously accept the recommendation to establish a redress agency, as set out in the Independent Medicines and Medical Devices Safety Review. However, the Government is carefully considering the valuable work done by the Patient Safety Commissioner and the resulting Hughes Report, published in February 2024, which recommended and set out options for redress for those harmed by valproate and pelvic mesh. We will be providing an update to the Patient Safety Commissioner’s report at the earliest opportunity.